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554Background: Z4032 was a randomized study conducted by the American College of Surgeons Oncology Group
comparing sublobar resection alone versus sublobar resection with brachytherapy for high-risk operable patients
with non–small cell lung cancer (NSCLC). This evaluates early impact of adjuvant brachytherapy on pulmonary
function tests, dyspnea, and perioperative (30-day) respiratory complications in this impaired patient population.
Methods: Eligible patients with stage I NSCLC tumors 3 cm or smaller were randomly allocated to undergo sublobar
resection with (SRB group) or without (SR group) brachytherapy. Outcomes measured included the percentage pre-
dicted forced expiratory volume in 1 second (FEV1%), percentage predicted carbon monoxide diffusion capacity
(DLCO%), and dyspnea score per the University of California San Diego Shortness of Breath Questionnaire. Pulmo-
nary morbidity was assessed per the Common Terminology Criteria for Adverse Events version 3.0. Outcomes were
measured at baseline and 3months. A 10% change in pulmonary function test or 10-point change in dyspnea scorewas
deemed clinically meaningful.
Results: Z4032 permanently closed to patient accrual in January 2010 at 224 patients. At 3-month follow-up, pulmo-
nary function data are currently available for 148 (74 SR and 74 SRB) patients described in this report. There were no
differences in baseline characteristics between arms. In the SR arm, 9 patients (12%) reported grade 3 respiratory ad-
verse events, compared with 12 (16%) in the SRB arm (P ¼ .49). There was no significant change in percentage
change in DLCO% or dyspnea score from baseline to 3 months within either arm. In the case of FEV1%, percentage
change from baseline to 3 months was significant within the SR arm (P¼ .03), with patients reporting improvement in
FEV1% at month 3. Multivariable regression analysis (adjusted for baseline values) showed no significant impact of
treatment arm, tumor location (upper vs other lobe), or surgical approach (video-assisted thoracoscopic surgery vs
thoracotomy) on 3-month FEV1%, DLCO%, and dyspnea score. There was no significant difference in incidence
of clinically meaningful (10% pulmonary function or 10-point dyspnea score change) change between arms.
Twenty-two percent of patients with lower-lobe tumors and 9% with upper-lobe tumors demonstrated 10% decline
in FEV1% (odds ratio, 2.79; 95 confidence interval, 1.07–7.25; P ¼ .04).
Conclusions: Adjuvant intraoperative brachytherapy in conjunction with sublobar resection did not significantly
worsen pulmonary function or dyspnea at 3 months in a high-risk population with NSCLC, nor was it associated
with increased perioperative pulmonary adverse events. Lower-lobe resection was the only factor significantly
associated with clinically meaningful decline in FEV1%. (J Thorac Cardiovasc Surg 2011;142:554-62)Earn CME credits at
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Abbreviations and Acronyms
CTCAE ¼ Common Terminology Criteria for
Adverse Events version 3.0
DLCO% ¼ percentage predicted carbon
monoxide diffusing capacity of the
lung
FEV1% ¼ percentage predicted forced
expiratory volume in 1 second
FVC ¼ forced vital capacity
NSCLC ¼ non–small cell lung cancer
SBRT ¼ stereotactic body radiation therapy
SR ¼ sublobar resection alone [group]
SRB ¼ sublobar resection with intraoperative
brachytherapy [group]
UCSD ¼ University of California San Diego
VATS ¼ video-assisted thoracoscopic surgery
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tomy.This studyhas recently completed accrual. The primary
aim of the study is local control, and results will be reported
when sufficient follow-up becomes available. This initial re-
port examines the effects of these procedures on pulmonary
function, dyspnea symptoms, and perioperative respiratory
complications to determine in particular any adverse effects
that brachytherapy might have in a patient group that is
already compromised from a pulmonary standpoint.
MATERIALS AND METHODS
Eligible patients for this study included patients with stage I lung can-
cers 3 cm or less in maximum diameter (stage IA or the subset of stage
IB with visceral pleural involvement) on preoperative computed tomo-
graphic scan. Patients were considered to be at high risk for lobectomy if
they met at least 1 major criterion or 2 minor criteria, as described in
Table 1. To facilitate enrollment, preregistration and random assignment
occurred before surgery to allow a diagnostic wedge resection to be per-
formed on the day of surgery. To confirm that patients did not have nodal
involvement, all suspicious lymph nodes seen on positron emission tomo-
graphic or computed tomographic scan required biopsy by mediastino-
scopy, by endobronchial or esophageal ultrasonography, or at the time of
resection. Sublobar resection included wedge or segmental resection and
could be performed by video-assisted thoracoscopic surgery (VATS) or
through a thoracotomy. The type of sublobar resection and approach
(VATS vs thoracotomy) was at the discretion of the treating surgeon.
Lymph node dissection or sampling was strongly encouraged but was not
mandatory in this high-risk population. Two methods of brachytherapy
were allowed.1,2 In the first technique, polyglactin sutures containing
iodine 125 seeds (Oncura Inc, Arlington Heights, Ill) were placed
parallel to and 5 mm away from the staple line on each side of the
resection margin. The suture strands were fixed to the lung surface with
several 3.0 silk or polyglactin sutures placed 1 to 2 cm apart. With the
second brachytherapy technique, a polyglycolic mesh implant was
created during the procedure. The same iodine 125 suture strands were
woven into a piece of polygalactin. The strands were placed at 1-cm inter-
vals. The mesh was then sutured over the staple line with 2.0 or 3.0 sutures.
The goal of the brachytherapy was to deliver 100 Gy at 5 to 7 mm along the
central axis of the resection margin.The Journal of Thoracic and CaThe primary objective of this phase III trial was to ascertain whether pa-
tients treated by sublobar resection with intraoperative brachytherapy
would have longer time to local recurrence than would patients treated
with sublobar resection alone. A secondary aim of this study was to assess
the effects of brachytherapy on pulmonary function, dyspnea symptoms,
and perioperative respiratory complications. In this article, we focus on
the pulmonary function results to month 3 by analyzing data from patients
for whom complete pulmonary function data were available at both
baseline and 3 months after surgery.
All patients provided written, informed consent before trial enrollment,
in accordance with applicable guidelines. At each participating site, insti-
tutional review board approval was obtained in accord with an assurance
filed with and approved by the United States Department of Health and
Human Services.
Data
Pulmonary function tests included percentage predicted forced expira-
tory volume in 1 second (FEV1%) and percentage predicted carbon
monoxide diffusing capacity of the lung (DLCO%), both of which were
measured preoperatively (baseline, day 0) and at 3 months after interven-
tion. These data will continue to be collected at 12 and 24 months post in-
tervention. Dyspnea score was measured with the University of California
San Diego (UCSD) Shortness of Breath Questionnaire at the same intervals
as the pulmonary function tests.3 The 24-item UCSD questionnaire uses
a 6-point scale (0 for not at all breathless to 5 for maximally breathless
or too breathless to do the activity) to assess the severity of each patient’s
self-reported shortness of breath. Dyspneawas also assessed with the Com-
mon Terminology Criteria for Adverse Events version 3.0 (CTCAE) at day
0 (baseline) and at 30 days and 3, 6, and 12 months after intervention. Pul-
monary and respiratory complications were assessed with the CTCAE and
included pneumonia from the infection category. It should be noted that the
CTCAE definition of prolonged intubation (>24 hours) is shorter in dura-
tion than the definition used in the Society of Thoracic Surgeons general
thoracic surgery database (>48 hours).
Statistical Analysis
Both c2 tests for categoric variables and Wilcoxon rank sum tests for
continuous variables were used to compare the baseline patient character-
istics between the SR and SRB arms. The grade 3 or higher perioperative
respiratory complications were compared between treatment arms with
the Fisher’s Exact test. The UCSD scale was reversed and scored by sum-
ming responses across all 24 items to form a total score ranging from 0 to
120. The total score was then transformed into a 0 to 100 scale, in which
0 represented worst dyspnea (poor quality of life) and 100 represented
no dyspnea (best quality of life). The median percentage changes in the
transformed UCSD dyspnea score, DLCO%, and FEV1% from baseline
to month 3 were compared within the SR and the SRB arms with a Wil-
coxon signed rank test. Additionally, a 10-point increase or decrease in
dyspnea score and a 10% increase or decrease in DLCO% or FEV1%
was deemed clinically meaningful and compared between the arms with
the Fisher’s Exact test. Exploratory logistic regression models were used
to assess the impact of surgical approach (VATS vs thoracotomy) and tumor
location (upper lobe vs other lobes) on clinically significant increases or de-
creases in DLCO%, FEV1%, and UCSD dyspnea score. In addition, gen-
eral linear models adjusting for baseline values were used to assess the
effects of treatment arm, surgical approach, and tumor location on the
3-month FEV1%, DLCO%, and dyspnea score, all considered as continu-
ous variables.
RESULTS
This trial met its target accrual and was permanently
closed as of January 22, 2010. A total of 224 patients
were registered. One patient in the SR arm had therdiovascular Surgery c Volume 142, Number 3 555
FIGURE 1. Patient cohort diagram. PFT, Pulmonary function test; IRB,
institutional review board; DLCO (%), percentage predicted diffusing ca-
pacity of the lung for carbon monoxide; % Predicted FEV1, percentage
predicted forced expiratory volume in 1 second.
TABLE 1. Major and minor eligibility criteria for Z4032 trial
Major criteria
1. Forced expiratory volume in 1 second 50% predicted
2. Diffusing capacity of the lung for carbon monoxide 50% predicted
Minor criteria
1. Age 75 y
2. Forced expiratory volume in 1 second 51%–60% predicted
3. Diffusing capacity of the lung for carbon monoxide 51%–60%
predicted
4. Pulmonary hypertension (defined as pulmonary artery systolic
pressure>40 mm Hg), as estimated by echocardiography or right
heart catheterization
5. Poor left ventricular function (defined as ejection fraction 40%)
6. Resting or exercise PaO255 mm Hg or peripheral oxygen saturation
88%
7. PCO2>45 mm Hg
8. Modified Medical Research Council Dyspnea Scale score 3.
Eligible patients must have met either 1 major criterion or 2 minor criteria.
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tional review board and thus was deemed not evaluable.
Sublobar resection alone was performed in 114 patients,
and sublobar resection with brachytherapy was performed
in 109 patients. Figure 1 shows the patient cohort diagram.
Data collection was frozen onMarch 9, 2010, for this anal-
ysis. At 3-month follow-up, complete pulmonary function
test data were available for 148 patients (n ¼ 74 SR, n ¼ 74
SRB). Of the 148 patients with baseline and 3-month
follow-up data, 12-month data were available for only 91
patients (n ¼ 40 SR, n ¼ 51 SRB); therefore, the 3-month
cohort is this review’s focus. Adjuvant chemotherapy was
not allowed with this protocol. If a patient was found after
resection to have a stage more advanced than IA, however,
adjuvant chemotherapy could be given at the treating physi-
cian’s discretion. At 3-month follow-up, only 3 patients
(4%) in the SR arm had received nonprotocol cancer therapy.
One patient received leuprolide acetate (Lupron, INN leu-
prorelin) injections for prostate cancer, and 2 patients re-
ceived- adjuvant cancer therapy for their primary NSCLC.
Baseline patient characteristics are summarized in Table
2. There were no differences between the arms. VATS was
undertaken in 51 SR group patients (69%) and 46 SRB
group patients (62%, P¼ .39). There were similar numbers
of upper-lobe tumors in each group, specifically 46 cases in
the SR group (62%) and 42 cases in the SRB group (57%,
P ¼ .50). The 3-month cohort was also similar to the re-
maining patients not included in this preliminary analysis
for both the SR and the SRB arms.
Data on grade 3 or higher perioperative (30-day) respira-
tory complications by arm are presented in Table 3. No
grade 5 respiratory complications were reported in either
arm. In the SR arm, 9 patients (12%) reported 11 grade 3
respiratory adverse events. In the SRB arm, 12 patients
(16%) reported 17 grade 3 respiratory adverse events; of
these, 1 patient also reported grade 4 hypoxia. This was556 The Journal of Thoracic and Cardiovascular Surgnot statistically significant (Fisher’s Exact test P ¼ .49).
There were 3 perioperative deaths (n ¼ 1 SR, n ¼ 2
SRB), 2 of patients who had lower-lobe resections. Two
deaths were attributed to cardiovascular events and 1 to pul-
monary embolus. One patient who died after a lower-lobe
sublobar resection had a baseline FEV1% of 25%.
Twenty-seven patients (n ¼ 13 SR, n ¼ 14 SRB) had
baseline FEV1% or DLCO% values less than 30%, with
6 patients (n¼ 1 SR, n¼ 5 SRB) having a value not greater
than 20%. Among these 27 patients, 2 patients reported
grade 3 respiratory complications (dyspnea) on day 30, 7
patients had a 10% decline in FEV1% or DLCO% at
month 3, and 6 patients had undergone lower-lobe resec-
tion. One patient had grade 3 hypoxia (required continuous
home oxygen therapy) at baseline. This patient had grade 4
hypoxia at 30 days. Seven additional patients had grade 3
hypoxia at 30 days, thus becoming oxygen dependent im-
mediately after treatment; however, no grade 3 or higher
hypoxia was reported at 3 months.
Baseline and 3-month pulmonary function test values and
dyspnea scores for the SR and SRB arms are provided in
Table 4. There was no significant change in the percentage
change in DLCO% or dyspnea score from baseline to 3
months within either arm. In the case of FEV1%, the per-
centage change from baseline to 3 months was significant
within the SR arm (P ¼ .03), with patients reporting an im-
provement in the median FEV1% from 49% to 53% at
month 3. Results from the general linear models (adjusted
for baseline values) showed no significant impact of treat-
ment arm, tumor location, or surgical approach on the
3-month values for FEV1%, DLCO%, and dyspnea score.
Table 5 summarizes the clinically meaningful changes
(increases or decreases of 10% or 10 points) from baselineery c September 2011
TABLE 2. Baseline patient characteristics
Factors
Month 3-cohort
Non–month 3 SR (n ¼ 40) vs
month 3 SR (n ¼ 74)
Non–month 3 SRB (n ¼ 35) vs
month 3 SRB (n ¼ 74)
SR (n ¼ 74) SRB (n ¼ 74) P value P value P value
Age (y, median and range) 70 (49–85) 71 (53–87) .69* .68* .18*
Sex (no.) >.999 .63 .91
Female 41 (55%) 41 (55%)
Male 33 (45%) 33 (45%)
Performance status (no.) .29 .51 .26
0 13 (18%) 21 (28%)
1 45 (61%) 39 (53%)
2 16 (21%) 14 (19%)
T stage (no.) .15 NA .34
T1 74 (100%) 72 (97%)
T2 0 (0%) 2 (3%)
M stage (no.) NA NA NA
M0 74 (100%) 74 (100%)
N stage (no.) .32 .17 .49
N0 74 (100%) 73 (99%)
N1 0 (0%) 1 (1%)
N2 0 (0%) 0 (0%)
Surgery in upper lobe (no.) .50 .17 .42
Yes 46 (62%) 42 (57%)
No 28 (38%) 32 (43%)
Surgery type (no.) .39 .90 .54
VATS 51 (69%) 46 (62%)
Thoracotomy 23 (31%) 28 (38%)
Surgery extent (no.) .07 .58 .07
Segmentectomy 26 (35%) 16 (22%)
Wedge resection 48 (65%) 58 (78%)
P values by c2 test except as marked. SR, Sublobar resection; SRB, sublobar resection with intraoperative brachytherapy; VATS, video-assisted thoracoscopic surgery; NA, not
applicable. *By Wilcoxon rank sum test.
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There were no statistically significant differences between
the groups with regard to the fractions of patients who
had meaningful changes in these parameters. At 3 months,
clinically meaningful declines in FEV1%, DLCO%, and
dyspnea score, respectively, occurred in 14%, 19%, and
21% of the SR group and in 15%, 30%, and 27% of the
SRB group. Clinically meaningful improvements in
FEV1%, DLCO%, and dyspnea score, respectively, oc-
curred in 19%, 19%, and 27% of the SR group and in
20%, 19%, and 34% of the SRB group. Most patients’ con-
ditions remained stable. Specifically, 68%, 62%, and 51%
of patients in the SR arm and 65%, 51%, and 38% in the
SRB arm had neither a clinically meaningful improvement
nor a clinically significant decline in FEV%, DLCO%, and
dyspnea score, respectively.
The effects of surgical approach (VATS vs thoracotomy),
tumor location, and development of grade 3 or 4 periopera-
tive respiratory complications on 3-month decline in DLCO
%, FEV%, and dyspnea score are summarized here. Of the
36 patients (n¼ 14 SR, n¼ 22 SRB) who had 10% decrease
in DLCO%, 21 patients (58%) had surgery in the upper-
lobe area, 14 (39%) had thoracotomy, and 5 (14%) hadThe Journal of Thoracic and Cagrade 3 or 4 perioperative respiratory complications. Of
the 21 patients (n ¼ 10 SR, n ¼ 11 SRB) who had a 10%
decrease in FEV1%, 8 patients (38%) had surgery in the
upper-lobe area and 7 (33%) had thoracotomy. No grade
3 or 4 respiratory complications were reported among these
patients. Thirty-five patients (n ¼ 15 SR, n ¼ 20 SRB) re-
ported a 10-point decrease in dyspnea score; of these, 25 pa-
tients (71%) had surgery in the upper-lobe area, 12 (34%)
had thoracotomy, and 4 (11%) had grade 3 or 4 respiratory
complications. There was no statistically significant impact
of the surgical approach or tumor location on clinically sig-
nificant changes in DLCO% and UCSD dyspnea scores
from baseline to month 3. There was, however, a significant
association between tumor location and a 10% decline in
FEV1%. Twenty-two percent of patients with lower-lobe
tumors versus only 9% of patients with upper-lobe tumors
had a 10% decline in FEV1% (odds ratio, 2.79; 95%
confidence interval, 1.07–7.25; P ¼ .04).DISCUSSION
Since the publication of the Lung Cancer Study Group’s
randomized comparison of lobectomy and sublobarrdiovascular Surgery c Volume 142, Number 3 557
TABLE 3. Grade 3 or higher perioperative (30-day) respiratory complications by arm
Grade
3 4 5
Adverse Event Arm No. % No. % No. %
All
No.
Infection or febrile neutropenia
Pneumonia* SR 1 1.4 0 0 0 0 1
SRB 3 4.1 0 0 0 0 3
Pulmonary
Adult respiratory distress syndrome SR 1 1.4 0 0 0 0 1
SRB 0 0 0 0 0 0 0
Dyspnea SR 5 6.9 0 0 0 0 5
SRB 7 9.5 0 0 0 0 7
Hypoxia SR 2 2.8 0 0 0 0 2
SRB 5 6.8 1 1.4 0 0 6
Pneumothorax SR 1 1.4 0 0 0 0 1
SRB 1 1.4 0 0 0 0 1
Prolonged air leak SR 1 1.4 0 0 0 0 1
SRB 0 0 0 0 0 0 0
Pulmonary, other SR 0 0 0 0 0 0 0
SRB 1 1.4 0 0 0 0 1
SR, Sublobar resection alone; SRB, sublobar resection with brachytherapy. *Pneumonia both with and without absolute neutrophil count specified.
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tients with stage I NSCLC. Currently, sublobar resection is
generally reserved as a compromise approach for high-risk
patients with impaired lung function. The impact of surgical
resection on these patients with baseline emphysema is
a significant concern. These considerations become even
more significant for treatment planning as nonresectional
therapies, such as stereotactic body radiation therapy
(SBRT) and radiofrequency ablation, become more widely
available.5-7
Miyazima and colleagues8 reported the effects of pulmo-
nary resection on early (4–6 months) and late (42–48
months) cardiopulmonary function. In their small patient
cohort (n ¼ 8), forced vital capacity (FVC) and maximum
voluntary ventilation were found to be significantly de-
creased at late follow-up. Interestingly, DLCO% decreased
from 85.4% to 79.5% at early follow-up but wasTABLE 4. Baseline and 3-month pulmonary function tests and dyspnea sc
Factor
SR
No. Baseline Month 3
Forced expiratory volume in 1
s (% predicted, median and
range)
74 49% (22%–117%) 53% (24%–101%
Diffusing capacity of lung for
carbon monoxide (%
predicted, median and
range)
74 46% (18%–97%) 48% (14%–144%
UCSD Shortness of Breath
Questionnaire score
(median and range)
73 75 (18–100) 79 (17–100)
SR, Sublobar resection; SRB, sublobar resection plus brachytherapy; UCSD, University of
signed rank test.
558 The Journal of Thoracic and Cardiovascular Surgsignificantly increased to 106.9% at late follow-up. In the
much larger randomized Lung Cancer Study Group study,4
pulmonary function tests were measured preoperatively and
at 6-month intervals; however, values were only obtained
for 60% of eligible patients who had at least 9-month
follow-up. At 6 months the changes from baseline for
forced expiratory volume in 1 second, FVC, and maximum
voluntary ventilation were significantly better in patients
undergoing sublobar resection than in those undergoing lo-
bar resection. At 12 to 18months, only the forced expiratory
volume in 1 second was statistically different between pa-
tients undergoing lobar and sublobar resection. Diffusing
capacity of the lung for carbon monoxide was not measured
in that study.
Keenan and associates9 compared pulmonary function
test values between 147 patients who underwent lobectomy
and 54 patients treated with segmental resection. At 1 year,ores by arm
SRB
P value* No. Baseline Month 3 P value*
) .03 74 51% (25%–110%) 53% (24%–104%) .18
) .38 74 46% (10%–137%) 43% (5%–96%) .16
.13 73 71 (6–98) 73 (27–100) .10
California San Diego. *Percentage change from baseline to 3-month value, Wilcoxon
ery c September 2011
TABLE 5. Distribution of clinically meaningful changes (10% change
in diffusion capacity of the lung for carbon monoxide percentage
predicted, 10% change in forced expiratory volume in 1 second
percentage predicted, and 10-unit change in University of California
San Diego Shortness of Breath Questionnaire score) from baseline to
month 3
Factor SR (n ¼ 74) SRB (n ¼ 74) P value*
Diffusing capacity of lung for
carbon monoxide,
percentage predicted
.29
Increase of 10% 14 (18.9%) 14 (18.9%)
Decrease 10% 14 (18.9%) 22 (29.7%)
Neither increase nor
decrease of 10%
46 (62.2%) 38 (51.4%)
Forced expiratory volume in
1 s, percentage predicted
.94
Increase of 10% 14 (18.9%) 15 (20.3%)
Decrease of 10% 10 (13.5%) 11 (14.9%)
Neither increase nor
decrease of 10%
50 (67.6%) 48 (64.9%)
University of California
Shortness of Breath
score (0–100)
.30
Missing 4 (5.4%) 1 (1.4%)
Increase of 10 units 19 (25.7%) 25 (33.8%)
Decrease of 10 units 15 (20.3%) 20 (27.0%)
Neither increase nor
decrease of 10 units
36 (48.6%) 28 (37.8%)
*By Fisher’s Exact test.
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voluntary ventilation, and DLCO% in the lobectomy group.
In contrast, in the segmentectomy group significant decline
was only seen in DLCO% which dropped from a mean of
67.5% to 55% (P¼ .0001). A recent study from Japanmea-
sured pulmonary function before and after segmentectomy
in 56 patients and compared these values with predicted
values after virtual lobectomy.10 The predicted values
were calculated by single-positron emission computed to-
mographic scan. FEV1%was significantly higher after seg-
mentectomy (88%) than the value for virtual lobectomy
(77%). Another interesting finding in this study was that
preservation of FEV1% was superior if only 1 or 2 seg-
ments were removed relative to removal of 3 or more seg-
ments. Left–upper lobe upper-division segmentectomy
(lingula-sparing lobectomy) also resulted in significantly
lower forced expiratory volume in 1 second than seen in pa-
tients undergoing lingular segmentectomy. These findings
suggest that segmental resection will preserve pulmonary
function primarily if small sublobar resections are under-
taken, whereas with larger sublobar resections (such as an
upper-lobe division segmentectomy) the benefit is mar-
ginal. Thus these procedures perhaps should only be re-
served for those patients with extremely compromised
function.The Journal of Thoracic and CaThe Cancer and Leukemia Group B11 previously reported
on a phase II trial of VATS wedge resection and local exter-
nal beam radiotherapy for NSCLC. Although 65 patients
were accrued, only 31 patients were ultimately eligible
for radiotherapy, with 28 receiving the protocol treatment.
Severe dyspnea was reported in 3 (11%) and moderate
pneumonitis in 4 (14%). This study illustrates the difficulty
in actually delivering planned external beam radiation
postoperatively to a high-risk patient group and the poten-
tial for harm from the radiation when it is delivered. The
advantage of intraoperative brachytherapy is that it can be
delivered at the same time as the lung resection with, it is
to be hoped, both lower radiation morbidity and improved
local tumor control.12 Sublobar resection with brachyther-
apy was initially reported in 1998 in a small series of 14
patients, 10 of whom required supplemental oxygen before
surgery.2 No significant radiation pneumonitis was ob-
served at a mean follow-up of 7 months. In this series, no
increased pulmonary morbidity was seen in the patient
group randomly assigned to brachytherapy.
In another series, 23 patients who underwent sublobar re-
section with mesh brachytherapy had follow-up pulmonary
function test measurements performed.13 No specific mor-
bidity related to the mesh implant was noted. Pulmonary
function was measured at baseline and 3 months but in-
cluded forced expiratory volume and FVC only. There
was no significant decline in either value at early follow-
up. Our preliminary 3-month data are consistent with these
findings. Relative to baseline values, there was no signifi-
cant decrease in FEV1% or DLCO% in either group.
Therapies such as radiofrequency ablation and SBRT,
which do not involve resection, are becoming increasingly
popular for patients with NSCLC. There have been only
a few reports documenting the effects of these therapies
on pulmonary function. A multicenter, prospective, non-
randomized trial of radiofrequency ablation included 22 pa-
tients with NSCLC who had pulmonary function test values
recorded to 12months.14 Therewas no significant decline in
FEV1% or percentage predicted FVC. It should be noted,
however, that baseline FEV1% was surprisingly high
(68.8%) in this series, suggesting that this was not a group
that most surgeons would regard as being at high risk. An-
other study reported on 20 patients who were treated with
CyberKnife (Accuray Incorporated, Sunnyvale, Calif) and
had serial measurements of pulmonary function tests re-
corded.15 Baseline FEV1% and DLCO% were 52% and
57%, respectively, which was consistent with this being
a high-risk group. Posttreatment FEV% did not change sig-
nificantly, although there were statistically significant de-
clines of DLCO% of 9% and 11% seen at 6 and 12
months, respectively. In another series of 70 patients treated
with SBRT, there was a 15.7% incidence of grade 3 to 5
toxicities, most of which were pulmonary-associated toxic-
ities.16 Additionally, in that series 27.7% of patientsrdiovascular Surgery c Volume 142, Number 3 559
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ygen was not specifically reported in our series; however,
the CTCAE defines grade 2 hypoxia as the need for inter-
mittent oxygen and grade 3 as the need for continuous ox-
ygen. Seven patients became oxygen dependent after
treatment (at 30 days); however, by 3 months none of these
patients were dependent on oxygen.
More recently, the Radiation Therapy and Oncology
group17 completed a phase II study of SBRT in high-risk pa-
tients. Grade 3 and 4 protocol-specific toxicities were re-
ported in 7 of 55 patients (12.7%) and 2 of 55 (3.6%),
respectively. All but 1 of these (8/55, 14.5%) of these tox-
icities were respiratory associated. In our series, 21 of 148
patients (14.2%) had perioperative grade 3 or 4 respiratory
complications, suggesting that even in a compromised pa-
tient population resection can be undertaken with similar
outcomes to SBRT. Currently, the American College of
Surgeons and the Radiation Therapy and Oncology Group
are developing a randomized study to compare SR and
SBRT in high-risk patients with lung cancer. Treatment-
related toxicity and effects on pulmonary function will be
key end points in this study.
In conclusion, in this randomized study of a patient co-
hort with stage I NSCLC at greater than average risk for lo-
bectomy, brachytherapy had no significant effect on lung
function at short-term follow-up. FEV1% and DLCO%
were equally preserved in both groups. The 30-day inci-
dences of grade 3 and 4 respiratory complications in the
SR and SRB arms were not significantly different.
Follow-up, including recording of pulmonary function, is
ongoing at the 12- and 24- month time points to ascertain
the long-term impact of brachytherapy on lung function.
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Dr Walter Weder (Zurich, Switzerland). Fernando and col-
leagues are to be congratulated for having initiated and now fin-
ished a prospective, multicenter, randomized trial evaluating an
important oncologic question. Today they report on a secondary
study end point, lung function and dyspnea. Dr Fernando, congrat-
ulations on your clear presentation and thanks for sending me the
manuscript long before the meeting. I have 3 questions. In your ar-
ticle, you discussed the Lung Cancer Study Group Trial, which
evaluated lobectomy versus sublobar resection and you com-
mented as follows about pulmonary function tests, ‘‘However,
values were only obtained for 60% of eligible patients who had
at least 9-month follow-up.’’ My comment on your study is the
same. Unfortunately, for only two thirds of the patients were the
pulmonary function test values available at 3 months, and for
less than half at 12 months. Why didn’t you wait a few more
months with your analysis and publication? This would have im-
proved the value of this report significantly.
I will continue with my second question. The patients you in-
cluded had either low forced expiratory volume in 1 second or
low diffusing capacity of the lung for carbon monoxide. I assume
this is typically the patient with emphysema. You also included,
however, patients with either high pulmonary artery pressure or
impaired left ventricular function, and the pulmonary function
test values in these patients were normal. So these are completely
different disease categories. My question is, why didn’t youery c September 2011
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Sanalyze these 2 groups of patients separately? I assume that any ef-
fect of brachytherapy on lung function could vary by disease cat-
egory. Finally, in your manuscript you mentioned that
endobrachytherapy delivers 100 Gy. What is the depth of the radi-
ation field of this locally applied radiation therapy?
Dr Fernando. Thank you very much. Those are great questions,
and I appreciate the challenge. I think that you picked up a major
point. We only have the 3-month data in detail. We debated how
much we should put into the discussion of 12-month data that
we had available. We decided that we could report what we have
at the moment, but as we get the longer and more complete
follow-up, we recognize that 12-month data results may change.
Analyzing the 12-month data is important, because radiation pneu-
monitis can be seen up to 6 months afterward. Currently, we don’t
see a difference at 12 months; however, that may change, and that
will be reported in detail when available.
In terms of analyzing the groups you mention separately, that’s
a good question. We didn’t—
DrWeder. Can I interrupt briefly? So what, then, is the value of
the current analysis? You said that the major impact of radiation
pneumonitis is at 3 to 6 months. If you are not waiting that time,
we get the report that tells us, ‘‘Yes, it may not have an impact,
but we are not really sure.’’ If you would have waited another 6
months, we would have the relevant information.
Dr Fernando. Well, the 12-month data would help answer the
question specifically about radiation pneumonitis, but not about
other pulmonary complications, which typically you can see in
the perioperative period up to 30 days. So I think that the 30-day in-
formation is still important. In previous studies, radiation pneumo-
nitis has not really been reported with brachytherapy, although that
is one of the things about which people remain concerned. We are
taking a patient population at greater than average risk, we’re sutur-
ing on the lung, we’re not using Peri-Strips, for instance, to buttress
the repair. Other surgeons are concerned about the risk of things
like prolonged air leaks, pneumonia, and even empyemas. We
didn’t see any empyemas in this group. So I think the longer fol-
low-up will really address the issue of radiation pneumonitis in
its own right, and hopefullywe can answer that question better then.
In terms of the second question, why we didn’t analyze the
groups separately, the data that we have on the data sheets that
the various site clinical research associates sent to us did not spe-
cifically separate out those groups. I think that’s a very interesting
question. We do have access to the source documents (the pulmo-
nary function test values), and so perhaps we will have to go back
and analyze that information, so that we can try and separate those
patients into those who maybe have more restrictive disease rather
than emphysema. I think that’s an excellent question, and some-
thing that we should address.
Can you remind me of the third question?
DrWeder.You mention in the manuscript that a 100-Gy dose is
delivered but say nothing about the depth of the radiation. Is it
a few millimeters, or more?
Dr Fernando. It’s about 5 to 7 mm or up to 1 cm, depending on
how strong those radiation seeds are. So, in effect, whatwe’re doing
is improving our margins. I’m not sure which patients this benefits,
but I suspect that the patients who will benefit are those patients
who have closewedge resections or closemarginwedge resections.
If you do a wedge resection with a 1-cmmargin or a margin at leastThe Journal of Thoracic and Cathe diameter of the tumor, or you do a good segmental resection,
probably the brachytherapy will not be as helpful.
Dr Weder. Thank you.
Dr Scott J. Swanson (Boston, Mass). Excellent paper. I thought
it was really useful to hear that information at this point. Did your
teams learn anything about how to put these seeds in, such that it
got easier over the course of the trial? Can you share any of that
technical information? Second, pertaining to that last point, can
you share any information about margins? Did you measure
margins? Do you have any data about margins?
Dr Fernando. I’ll take the margin question first. I’ve gone
through the reviews that I’ve done thus far. One of the secondary
end points we had was to look at staple-line cytology. There are
some Japanese data, I think by Sawabata, where he swiped the
specimen on a glass slide and found differences between the
staple-line cytology and the actual histology. He even identified
patients who had positive staple-line cytology yet negative histol-
ogy. So we put that in as a secondary end point that we’re measur-
ing, and those data will eventually be presented. But what’s
interesting, as I read through the reports, is that people are actually
getting reads from their cytologists in there and they are going
back and taking bigger and bigger margins. So I think as a group,
the surgeons are actually doing better wedge resections or better
segments than maybe in previous studies. So far I have not seen
lot of local recurrences in the cases that I’ve analyzed.
The second thing, in terms of what have I learned, in terms of
a thoracoscopic approach, I personally like to use the Endo-Stitch
a lot, and I found with some of the Vicryl meshes that we have that
the Endo-Stitch does not sew very well through the mesh, and the
needle tends to get stuck. It’s a blunter needle. So I changed to us-
ing a standard needle, and what I do is I place the stitch through the
mesh and then into the lung, bring it up, and I have 2 long strands
of suture. Rather than trying to do an endoscopic tie, what I do is I
simply put a series of clips along the suture. So the clips serve as
my tie on the suture, and that also avoids having to actually do an
intracorporeal knot in the patient.
Dr Nasser K. Altorki (New York, NY). I enjoyed your presen-
tation. I want to agree a little bit with you and a little bit with
Walter. He made his point, but I think that there is a real issue of
delivering 100 Gy to a fresh suture line, and I think all of us
who do this worry about the issues that you described. I think in
that sense your report is helpful. Can you share with us issues
that relate to radiation exposure in the operating room? What do
you do? What is the risk to people in the room? You sew it. Do
you wear radioprotective gloves? Do you wear a shield?
Dr Robert J. Cerfolio (Birmingham, Ala). And any surgical
team members who might be pregnant in the operating room,
which is an issue.
Dr Fernando. That issue of radiation safety has been reported
in another article, with data not from this study but from a previous
single-center study (Smith RP, Schuchert M, Komanduri K,
Burton S, Heron DE, Luketich JD, et al. Dosimetric evaluation
of radiation exposure during I-125 vicryl mesh implants: implica-
tions for ACOSOG z4032. Ann Surg Oncol. 2007;14:3610-3). You
have to follow the regulations in place in your own hospital and
within your own state. I wear a lead apron when I do this. I try
not to handle the seeds directly, for instance not tying right
down into the knot with my fingers. When the implant is prepared,rdiovascular Surgery c Volume 142, Number 3 561
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Swhat you do is basically to place all the sutures in place into the
mesh with a lead shield over the active radiation seeds, and then
when you’re ready, you have all 4 sutures with the seeds into
the mesh. You pull each suture through, so that you are minimiz-
ing radiation exposure. The radiation physicist is in the room mea-
suring the radiation in the room and around the room. In terms of
actual safety for the patient, it’s really very safe. It’s a low dose
rate brachytherapy. And the falloff is rapid as you move away
from the source. In the study I just mentioned, dosimeters placed
on the patient’s shoulder measured very low doses of radiation in
these patients who had an implant placed. So it’s actually a low
dose of radiation exposure.
Dr Altorki. There is a glove that is lead impregnated that you
could use.562 The Journal of Thoracic and Cardiovascular SurgDr Daniel L. Miller (Atlanta, Ga). With regard to placement,
what we at Emory and some other surgeons throughout the United
States have been using is the pericardial Veritas strip, which is a lit-
tle bit wider. They have a wider version, and it’s very easy to han-
dle. You bring the suture out, and you clip the radiation seed suture
onto the buttress material. So you have no extra holes into the lung.
When you have expansion of the lung, there’s no tearing and so
forth. It really minimizes the amount of time spent handling the
radiation, and you’re not suturing into the lung in a way that
may produce prolonged air leaks and so forth. I know that wasn’t
allowed in this portion of the study, it’s off-study; however, I think
that in the future this is another way to look at that, to minimize
other lung problems and so forth.
Dr Fernando. Thank you.ery c September 2011
